KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Non-Current Deferred Tax Liability: 2013-2024

Historic Non-Current Deferred Tax Liability for Emergent BioSolutions (EBS) over the last 8 years, with Dec 2024 value amounting to $41.7 million.

  • Emergent BioSolutions' Non-Current Deferred Tax Liability fell 13.37% to $36.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.3 million, marking a year-over-year decrease of 13.37%. This contributed to the annual value of $41.7 million for FY2024, which is 29.20% down from last year.
  • Emergent BioSolutions' Non-Current Deferred Tax Liability amounted to $41.7 million in FY2024, which was down 29.20% from $58.9 million recorded in FY2023.
  • Over the past 5 years, Emergent BioSolutions' Non-Current Deferred Tax Liability peaked at $130.7 million during FY2021, and registered a low of $41.7 million during FY2024.
  • Its 3-year average for Non-Current Deferred Tax Liability is $75.3 million, with a median of $58.9 million in 2023.
  • Per our database at Business Quant, Emergent BioSolutions' Non-Current Deferred Tax Liability climbed by 11.52% in 2021 and then tumbled by 53.03% in 2023.
  • Yearly analysis of 5 years shows Emergent BioSolutions' Non-Current Deferred Tax Liability stood at $117.2 million in 2020, then climbed by 11.52% to $130.7 million in 2021, then dropped by 4.06% to $125.4 million in 2022, then tumbled by 53.03% to $58.9 million in 2023, then fell by 29.20% to $41.7 million in 2024.